Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Oral Talazoparib in Advanced Solid Tumors
NCT03426254Phase 1Withdrawn
- Sponsor
- Center Trials & Treatment
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of talazoparib in solid tumor (advanced stage) and breast cancer (2 arms), sponsored by Center Trials & Treatment. Primary endpoint: Frequency of occurrence and evaluation of adverse events at 12 months. Planned start Nov 2022; status: withdrawn.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT03426254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426254.